XBiotech Inc.

XBIT Healthcare Biotechnology

XBiotech Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.0 million. In the quarter to June 2026, EPS fell 266.7% and free cash flow grew 25.3%, each against the same quarter a year earlier.

2.12 0.04 −1.85%
Market cap
$65.9M
P/E
0.0×
Fwd P/E
−3.3×
Dividend yield
—
F-score
3/9
Altman Z
11.69
Beneish M
−4.17
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
41.48 15.88 38.60 32.75
Current Ratio
41.78 16.01 39.03 33.15
Net Debt/EBITDA
26.22 4.27 19.43 18.74
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.71 0.85 1.63 0.67
Capex/Depreciation
(0.26) (0.09) 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.14) (0.75) (0.29) (0.15)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.14) (0.75) (0.29) (0.15)
Cash per Share
4.83 4.12 3.79 3.59
Shareholders Equity per Share
5.48 4.60 4.43 4.21
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
5.48 4.60 4.43 4.21
Free Cash Flow
(4.37) (22.99) (8.97) (4.51)
Working Capital
145.39 119.02 114.05 107.81
Capital Expenditures
(0.11) (0.03) — —
Net Current Asset Value
143.61 117.22 112.23 105.97
EV/EBIT
— — — —
Capex to Sales
0.00 0.00 — —
Other line items
Average Receivables
0.70 0.61 0.47 0.46
Average Payables
1.27 1.88 0.98 1.27
Average Assets
191.14 174.59 160.85 156.17
Average Common Equity
179.60 161.31 154.87 150.76

Fold the line items

Columns are period end dates